Urinary Tract Infections in Children

Diagnosis and Treatment

• The American Academy of Pediatrics recommends amoxicillin-clavulanic acid as the first-line treatment for pediatric urinary tract infections, with sulfamethoxazole-trimethoprim as an appropriate alternative, at a dose of 20-40 mg/kg/day divided in 3 doses for amoxicillin-clavulanic acid and 6-12 mg/kg trimethoprim and 30-60 mg/kg sulfamethoxazole per day in 2 doses for sulfamethoxazole-trimethoprim, with a strength of evidence level of high 1
• Significant bacteriuria is defined as ≥50,000 CFU/mL of a single uropathogen, and urine culture should be obtained before starting antibiotics to confirm diagnosis and guide therapy, as recommended by The Journal of Urology 2 and the European Urology guidelines 3, with a strength of evidence level of high 1
• Local resistance patterns should be considered when choosing empiric therapy, and treatment should be modified according to culture results when available, as recommended by the Infectious Diseases Society of America 4, with a strength of evidence level of moderate 1
• The American Academy of Pediatrics also recommends avoiding treatment of asymptomatic bacteriuria as it may be harmful and contribute to antimicrobial resistance, with a strength of evidence level of high 1
• Stringent diagnostic criteria are important to avoid overdiagnosis and unnecessary treatment, with a strength of evidence level of moderate 1
• Follow-up urine culture 1-2 weeks after treatment completion is recommended to ensure cure, although the exact timing may vary depending on individual patient needs, as recommended by 5, with a strength of evidence level of low

Antibiotic Choices

• Amoxicillin-clavulanic acid or sulfamethoxazole-trimethoprim are recommended as first-line oral options, with nitrofurantoin as a second choice, as recommended by the Infectious Diseases Society of America 4, with a strength of evidence level of high 6
• Ceftriaxone or cefotaxime are recommended as first-line parenteral options, with ciprofloxacin as a second choice for older children, as recommended by the European Urology Association 3, with a strength of evidence level of moderate 6
• The European Urology Association recommends cephalosporins such as cefadroxil (500 mg twice daily for 3 days) as an alternative treatment option, with a strength of evidence level of low 3
• For uncomplicated lower UTI, the European Urology Association recommends cephalosporins as the first choice if local E. coli resistance is less than 20%, with a strength of evidence level of moderate 3

Treatment Duration

• The treatment duration for uncomplicated UTIs is 7-14 days, as recommended by the American Academy of Pediatrics 1, with a strength of evidence level of high
• Initial parenteral therapy with ceftriaxone or cefotaxime should be switched to oral therapy when the patient is clinically improved and afebrile for 24 hours, with a total treatment duration of 10-14 days, as recommended by the Infectious Diseases Society of America 4, with a strength of evidence level of moderate
• The recommended treatment duration for lower UTIs is 3-5 days, as recommended by the Infectious Diseases Society of America 4, and 7 days, as recommended by the World Health Organization 6 and the American Academy of Pediatrics 1, with a strength of evidence level of moderate
• The treatment duration for pyelonephritis or upper UTI is 7-14 days, as recommended by the European Association of Urology 3 and the American Academy of Pediatrics 1, with a strength of evidence level of high

Complicated UTIs

• Complicated UTIs are defined by factors such as urinary tract obstruction, foreign body, incomplete voiding, vesicoureteral reflux, recent instrumentation, diabetes, immunosuppression, or healthcare-associated infections, and include male UTIs and presence of multidrug-resistant organisms or ESBL-producing organisms, as recommended by the European Urology Association 3, with a strength of evidence level of moderate
• The treatment duration for complicated UTIs is 7 days for most cases, but may be extended to 14 days for men when prostatitis cannot be excluded, and may consider shorter duration (7 days) when patient is hemodynamically stable and afebrile for at least 48 hours, as recommended by the European Urology Association 3, with a strength of evidence level of moderate
• For complicated UTIs with systemic symptoms, European guidelines recommend combinations like amoxicillin plus an aminoglycoside or a second/third-generation cephalosporin plus an aminoglycoside, with a strength of evidence level of low 3
• The recommended treatment options for complicated UTIs are:

Special Populations

• Nitrofurantoin is recommended as a first-choice option for treating lower urinary tract infections in pregnant women due to its high susceptibility rates against E. coli and favorable risk-benefit profile, as recommended by the World Health Organization 6, with a strength of evidence level of high
• Sulfamethoxazole-trimethoprim may be used as an alternative option for UTIs in pregnant women, but should be avoided in the first trimester and near term, as recommended by 6, 5, with a strength of evidence level of moderate
• Fluoroquinolones (such as ciprofloxacin) should be avoided unless absolutely necessary and other options are inappropriate due to safety concerns and high resistance potential, as recommended by 6, with a strength of evidence level of high
• Macrolides (azithromycin, clarithromycin) should be avoided as they have poor efficacy against common UTI pathogens and increasing resistance in respiratory pathogens, as recommended by 7, 8, with a strength of evidence level of moderate
• The American Academy of Pediatrics recommends amoxicillin-clavulanate as first-line therapy for empiric treatment in children aged 2-24 months, with a dosage of 40-50 mg/kg/day orally in 3 divided doses for 7 days, and has demonstrated high efficacy in pediatric UTIs (89-96% clearance rate), with a strength of evidence level of high 1, 7

Monitoring and Adverse Effects

• Monitoring for adverse effects of antibiotics, including diarrhea, rash and allergic reactions, and C. difficile colitis, especially with repeated or prolonged antibiotic courses, as noted by the American Academy of Pediatrics 7, with a strength of evidence level of moderate
• Treating asymptomatic bacteriuria may be harmful and contribute to antimicrobial resistance, as stated by the American Academy of Pediatrics 1, with a strength of evidence level of high
• The European Urology Association recommends considering renal function when dosing fluoroquinolones in elderly patients, with a strength of evidence level of low 3
• The Infectious Diseases Society of America recommends considering local resistance patterns when choosing empiric therapy and adjusting treatment based on culture results when available, with a strength of evidence level of moderate 4